Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Interacting Proteins Key to Melanoma Development Identified

By R&D Editors | May 6, 2008

Researchers have discovered how a mole develops into melanoma by showing the interaction of two key proteins involved in 60-70 percent of tumors. The Penn State scientists also demonstrate that therapeutic targeting of these proteins is necessary for drugs to effectively treat this form of cancer.

“We have shown that when two proteins—(V600E)B-Raf and Akt3—communicate with one another in a mole, they cooperate leading to the development of melanoma,” said Gavin Robertson, lead author and associate professor of pharmacology, pathology and dermatology, and director of the Foreman Foundation Melanoma Therapeutics Program at the Penn State College of Medicine Cancer Institute. “We have also shown that effective therapies for melanoma need to target both these proteins, which essentially eliminates the tumors.”

Melanoma is the most deadly form of skin cancer because it metastasizes or moves around the body so quickly. In general, people with advanced-stage disease only have months to live. Currently, melanoma kills one person every hour in the U.S., and is predicted to affect one in 50 people by 2010. In recent years, researchers have zeroed in on two key genes—B-Raf and Akt3—that cause this deadly cancer, and which could be important targets in the treatment of melanoma.

B-Raf is the most mutated gene in melanoma. The mutant protein, (V600E)B-Raf, produced by this gene is important in helping mole cells survive and grow but it is unable to form melanomas on its own. Nearly 90 percent of all moles have the mutant protein but it is not fully clear why only some of them turn into melanomas.

Robertson and his colleagues have found that a second protein—produced by Akt3—regulates the activity of the mutated B-Raf, which aids the development of melanoma.

Release date: May 6, 2008
Source: Penn State 

Related Articles Read More >

Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
Thermo Fisher Scientific and Qatar Genome Program partner to advance precision medicine 
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars